{'fraction_non_alphanumeric': 0.020465116279069766, 'fraction_numerical': 0.011162790697674419, 'mean_word_length': 5.183908045977011, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Rational design and construction of HER2 targeting recombinant human serum albumin

HER2 (Human Epidermal growth factor Receptor 2) is a receptor over expressed in approximately 30% of human breast cancers. Human Serum Albumin (HSA) is the main protein in plasma, its biophysical and biochemical properties make it an ideal candidate for drug delivery. The overall purpose of this study is to develop an HSA‐based drug delivery system capable of targeting HER2 to enhance tumor drug delivery. Several HER2 binding peptides were utilized here. The DNA sequences of these peptides were designed, synthesized and integrated into HSA gene and the recombinant proteins were expressed. The binding affinity of purified proteins to HER2 was tested in SK‐BR‐3 cells and showed specific recognition of HER2. It is hoped that our design can serve as 1) a scaffold to produce highly specific, targeted proteins, or 2) an approach to create bi‐specific proteins capable of promoting a synergistic effect on the inhibition of cancer cell growth when combined with chemotherapeutic agents.